Oberland pours up to $400M into MeiraGTx eye gene therapies
AI Summary
Oberland is investing up to $400 million in MeiraGTx to advance eye gene therapies in late-stage development, including a promising asset recently reacquired from Johnson & Johnson. This funding reflects confidence in the commercial potential of these therapies.
The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development β one of which MeiraGTx recently reacquired from J&J.